MIA 2021, Manejo Integral del Asma. Lineamientos para México

Autores/as

DOI:

https://doi.org/10.29262/ram.v68i5.880

Palabras clave:

Asma, Guía de práctica clínica, Biomarcador, Tratamiento biológico

Resumen

Antecedentes: El asma sigue siendo una patología respiratoria crónica frecuente en México. Se han descrito nuevos métodos para el diagnóstico y tratamiento conforme se renuevan las guías internacionales.

Objetivo: Crear la plataforma nacional Manejo Integral del Asma (MIA), para el desarrollo de lineamientos actualizados con base en evidencia.

Métodos: Se utilizó el método ADAPTE. El grupo de desarrollo de MIA estuvo integrado por expertos en neumología, alergología y metodología y representantes de 13 instituciones y sociedades de especialidades que manejan asma. Las guías internacionales de referencia (seleccionadas con AGREE-II) fueron GINA 2020, GEMA 5.0, BTS/SIGN 2019 y consenso ATS/ERS 2014-2019. En MIA se aborda sospecha de asma, diagnóstico, tratamiento y grupos especiales. Se formularon preguntas clínicas clave sobre tratamiento en los pasos 1 a 3, biomarcadores y asma grave.

Resultados: Con base en evidencia, seguridad, costo y realidad local, el grupo nuclear desarrolló respuestas. Mediante proceso Delphi, el grupo amplio de desarrollo sugirió ajustes hasta que se logró el consenso.

Conclusión: El documento generado contiene múltiples figuras y algoritmos, está sólidamente basado en evidencia acerca del manejo del asma y fue ajustado para México con participación de diferentes sociedades para su desarrollo; no se incluyeron lineamientos para la crisis asmática.

Citas

worldwide asthma prevalence. Eur Respir J. 2020;56(6):2002094 DOI: 10.1183/13993003.02094-2020

Carrillo G, Méndez-Domínguez N, Datta-Banik R, Figueroa-López F, Estrella-Chan B, Álvarez-Baeza A, et al. Asthma mortality and hospitalizations in Mexico from 2010 to 2018: retrospective epidemiologic profile. Int J Environ Res Public Health. 2020;17(14):5071. DOI: 10.3390/ijerph17145071

Larenas-Linnemann D, Salas-Hernández J, Vázquez-García JC, Ortiz-Aldana I, Fernández-Vega M, Del Río-Navarro BE, et al. Guía Mexicana del Asma: GUIMA 2017. Rev Alerg Mex. 2017;64 Supl 1:s11-s128. DOI: 10.29262/ram.v64i0.272

Tratamiento del asma en edad pediátrica. Guía de Práctica Clínica: evidencias y recomendaciones [Internet]. México: Centro Nacional de Excelencia Tecnológica en Salud; 2020. Disponible en: http://www.cenetec-difusion.com/CMGPC/GPC-SS-009-20/ER.pdf

SIGN 158. British Guideline on the Management of Asthma. A national clinical guideline [Internet]. Reino Unido: British Thoracic Society/National Health Service Scotland; 2019. Disponible en: https://www.brit-thoracic.org.uk/document-library/guidelines/asthma/btssign-guideline-for-the-management-of-asthma-2019/

Global Initiative for Asthma [Internet]. Global Strategy for Asthma Management and Prevention; 2019. Disponible en: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf

GEMA 5.0. Guía Española para el Manejo del Asma [Internet]. España: Luzán 5; 2020. Disponible en: https://www.semg.es/images/documentos/GEMA_5.0.pdf

Holguín F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. DOI: 10.1183/13993003.00588-2019

Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219-233. DOI: 10.1007/s12016-018-8712-1

Godar M, Blanchetot C, de Haard H, Lambrecht BN, Brusselle G. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. MAbs. 2018;10(1):34-45. DOI: 10.1080/19420862.2017.1392425

Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377(10):965-976. DOI: 10.1056/NEJMra1608969

Martínez-Briseño D, Gochicoa-Rangel L, Torre-Bouscoulet L, Cid-Juárez S, Fernández-Plata R, Martínez-Valdeavellano L, et al. Comparing spirometric reference values from childhood to old age estimated by LMS and linear regression models. Arch Bronconeumol. 2021;57(3):172-178. DOI: 10.1016/j.arbres.2019.12.033

Gochicoa-Rangel L, Vázquez-García J, Vargas-Domínguez C, Velázquez-Uncal M, et al. Bronchial challenge test with exercise: recommendations and procedure. Neumol Cir Torax. 2019;78(Suppl 2):S198-S211. Disponible en: https://www.medigraphic.com/pdfs/neumo/nt-2019/nts192m.pdf

Bedolla-Barajas M, Ortiz-Peregrina JR, Hernández-Colín DD, Morales-Romero J, Bedolla-Pulido TR, Larenas-Linnemann D. The characterization of asthma with blood eosinophilia in adults in Latin America. J Asthma. 2019;56(11):1138-1146. DOI: 10.1080/02770903.2018.1520863

Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007;30(3):452-456. DOI: 10.1183/09031936.00165106

O’Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW, START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009;179(1):19-24. DOI: 10.1164/rccm.200807-1126OC

Ortega H, Yancey SW, Keene ON, Gunsoy NB, Albers FC, Howarth PH. Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2018;6(3):980-986. DOI: 10.1016/j.jaip.2017.12.019

Del Río-Navarro BE, Berber A, Reyes-Noriega N, Navarrete-Rodríguez EM, García-Almaraz R, Ellwood P, et al. Global Asthma Network Phase I study in Mexico: prevalence of asthma symptoms, risk factors and altitude associations-a cross-sectional study. BMJ Open Respir Res. 2020;7(1):e000658. DOI: 10.1136/bmjresp-2020-000658

Biagini-Myers JM, Schauberger E, He H, Martin LJ, Kroner J, Hill GM, et al. A Pediatric Asthma Risk Score to better predict asthma development in young children. J Allergy Clin Immunol. 2019;143(5):1803-1810. DOI: 10.1136/bmjresp-2020-000658

GEMA 4.0. Guía española para el manejo del asma. Arch Bronconeumol. 2015;51(Suppl 1):2-54. DOI: 10.1016/S0300-2896(15)32812-X

Larenas-Linnemann D, Salas-Hernández J, Vázquez-García JC, Ortiz-Aldana I, Fernández-Vega M, del Río-Navarro BE, et al. Guía Mexicana del Asma: GUIMA 2017. Alerg Mex. 2017;64(Supl 1):s11-s128. DOI: 10.29262/ram.v64i0.272

Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B, et al. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis. 2010;5:311-318. DOI: 10.2147/copd.s12120

Van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J. 1996;9(8):1684-1688. DOI: 10.1183/09031936.96.09081684

Axelsson I, Naumburg E, Prietsch SO, Zhang L. Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth. Cochrane Database Syst Rev. 2019;6(6):CD010126. DOI: 10.1002/14651858.CD010126.pub2

Agache I, Beltrán J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023-1042. DOI: 10.1111/all.14221

Murphy KR, Hong JG, Wandalsen G, Larenas-Linnemann D, El Beleidy A, Zaytseva OV, et al. Nebulized inhaled corticosteroids in asthma treatment in children 5 years or younger: a systematic review and global expert analysis. J Allergy Clin Immunol Pract. 2020;8(6):1815-1827. DOI: 10.1016/j.jaip.2020.01.042

Martínez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9766):650-657. DOI: 10.1016/S0140-6736(10)62145-9

Plaza V, Fernández-Rodríguez C, Melero C, Cosío BG, Entrenas LM, de Llano LP, et al. Validation of the ‘Test of the Adherence to Inhalers’ (TAI) for asthma and COPD patients. J Aerosol Med Pulm Drug Deliv. 2016;29(2):142-152. DOI: 10.1089/jamp.2015.1212

Rodríguez-Santos O. Sublingual immunotherapy in allergic rhinitis and asthma in 2-5 year-old children sensitized to mites. Rev Alerg Mex. 2008;55(2):71-75.

Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy. 2005;60(1):133. DOI: 10.1111/j.1398-9995.2004.00616.x

Larenas-Linnemann D, Luna-Pech JA, Rodríguez-Pérez N, Rodríguez-González M, Arias-Cruz A, Blandon-Vijil MV, et al. GUIMIT 2019, Guía Mexicana de Inmunoterapia. Guía de diagnóstico de alergia mediada por IgE e inmunoterapia aplicando el método ADAPTE. Rev Alerg Mex. 2019;66(Supl 1):1-105. DOI: 10.29262/ram.v66i5.631

Vrijlandt E, Azzi G, Vandewalker M, Rupp N, Harper T, Graham L, et al. Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2018;6(2):127-137. DOI: 10.1016/S2213-2600(18)30012-2

Parra-Padilla D, Zakzuk J, Carrasquilla M, Alvis-Guzmán N, Dennis R, Rojas MX, et al. Cost-effectiveness of the subcutaneous house dust mite allergen immunotherapy plus pharmacotherapy for allergic asthma: A mathematical model. Allergy. 2020. DOI: 10.1111/all.14723

Larenas-Linnemann D, Gochicoa-Rangel L, Macías-Weinmann A, Soto-Ramos M, Luna-Pech JA, Elizondo-Ríos A, et al. Consenso mexicano en relación con la fracción exhalada de óxido nítrico (FeNO) en asma 2020. Rev Alerg Mex. 2020;67(Supl 2):s1-s25. DOI: 10.29262/ram.v67i0.760

Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896-902. DOI: 10.1016/j.jaci.2014.08.042

Larsson K, Ställberg B, Lisspers K, Telg G, Johansson G, Thuresson M, et al. Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR). Respir Res. 2018;19(1):12. DOI: 10.1186/s12931-018-0719-x

Richards LB, Neerincx AH, van Bragt J, Sterk PJ, Bel EHD, Maitland-van der Zee AH. Biomarkers and asthma management: analysis and potential applications. Curr Opin Allergy Clin Immunol. 2018;18(2):96-108. DOI: 10.1097/ACI.0000000000000426

Mogensen I, James A, Malinovschi A. Systemic and breath biomarkers for asthma: an update. Curr Opin Allergy Clinical Immunol. 2020;20(1):71-79. DOI: 10.1097/ACI.0000000000000599

Contreras-Omaña R, Sánchez-Reyes O, Ángeles-Granados E. Comparison of the Carlsson-Dent and GERD-Q questionnaires for gastroesophageal reflux disease symptom detection in a general population. Rev Gastroenterol Mex. 2017;82(1):19-25. DOI: 10.1016/j.rgmx.2016.05.005

Traister RS, Fajt ML, Landsittel D, Petrov AA. A novel scoring system to distinguish vocal cord dysfunction from asthma. J Allergy Clin Immunol Pract. 2014;2(1):65-69. DOI: 10.1016/j.jaip.2013.09.002

Amra B, Rahmati B, Soltaninejad F, Feizi A. Screening questionnaires for obstructive sleep apnea: an updated systematic review. Oman Med J. 2018;33(3):184-92. DOI: 10.5001/omj.2018.36

Bardin PG, Rangaswamy J, Yo SW. Managing comorbid conditions in severe asthma. Med J Aust. 2018;209(S2):S11-S17. DOI: 10.5694/mja18.00196

Lee SH, Ban GY, Kim SC, Chung CG, Lee HY, Lee JH, et al. Association between primary immunodeficiency and asthma exacerbation in adult asthmatics. Korean J Intern Med. 2020;35(2):449-456. DOI: 10.3904/kjim.2018.413

Keswani A, Dunn NM, Manzur A, Kashani S, Bossuyt X, Grammer LC, et al. The clinical significance of specific antibody deficiency (SAD) severity in chronic rhinosinusitis (CRS). J Allergy Clin Immunol Pract. 2017;5(4):1105-1111. DOI: 10.1016/j.jaip.2016.11.033

Berti A, Cornec D, Casal-Moura M, Smyth RJ, Dagna L, Specks U, et al. Eosinophilic granulomatosis with polyangiitis: clinical predictors of long-term asthma severity. Chest. 2020;157(5):1086-1099. DOI: 10.1016/j.chest.2019.11.045

Crimi C, Ferri S, Crimi N. Bronchiectasis and asthma: a dangerous liaison? Curr Opin Allergy Clin Immunol. 2019;19(1):46-52. DOI: 10.1097/ACI.0000000000000492

Moss RB. Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. Eur Respir J. 2014;43(5):1487-1500. DOI: 10.1183/09031936.00139513

Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999;14(1):32-38. DOI: 10.1034/j.1399-3003.1999.14a08.x

Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5(1):35-46. DOI: 10.1007/BF00435967

Suehs CM, Menzies-Gow A, Price D, Bleecker ER, Canonica GW, Gurnell M, et al. Expert consensus on the tapering of oral corticosteroids for the treatment of asthma: a Delphi study. Am J Respir Crit Care Med. 2020;203(7):871-881. DOI: 10.1164/rccm.202007-2721OC

Alves C, Robazzi TC, Mendonca M. Withdrawal from glucocorticosteroid therapy: clinical practice recommendations. J Pediatr (Rio J). 2008;84(3):192-202. DOI:10.2223/JPED.1773

Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-615. DOI: 10.1164/rccm.9120-11ST

Panickar JR, Kenia P, Silverman M, Grigg J. Intramuscular triamcinolone for difficult asthma. Pediatr Pulmonol. 2005;39(5):421-425. DOI: 10.1002/ppul.20176

Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804-811. DOI: 10.1164/rccm.201208-1414OC

Busse W, Spector S, Rosen K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013;132(2):485-486. DOI: 10.1016/j.jaci.2013.02.032

Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-1197. DOI: 10.1056/NEJMoa1403291

Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-1207. DOI: 10.1056/NEJMoa1403290

Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390-400. DOI: 10.1016/S2213-2600(17)30125-X

Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789-798. DOI: 10.1016/j.chest.2016.03.032

Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125-1132. DOI: 10.1164/rccm.201103-0396OC

Castro M, Zangrilli J, Wechsler ME, Bateman ED, Bruselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(4):355-366. DOI: 10.1016/S2213-2600(15)00042-9

Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 Study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799-810. DOI: 10.1016/j.chest.2016.03.018

FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor  monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128-2141. DOI: 10.1016/S0140-6736(16)31322-8

Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115-2127. DOI: 10.4168/aair.2019.11.4.508

Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879-890. DOI: 10.1016/S2213-2600(14)70201-2

Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448-2458. DOI: 10.1056/NEJMoa1703501

Park HS, Kim MK, Imai N, Nakanishi T, Adachi M, Ohta K, et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int Arch Allergy Immunol. 2016;169(3):135-145. DOI: 10.1159/000444799

Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting 2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31-44. DOI: 10.1016/S0140-6736(16)30307-5

Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485. DOI: 10.1056/NEJMoa1804093

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496. DOI: 10.1056/NEJMoa1804092

Corren J, Castro M, O’Riordan T, Hanania NA, Pavord ID, Quirce S, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 2020;8(2):516-526. DOI: 10.1016/j.jaip.2019.08.050

Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, et al. Characterization of severe asthma worldwide: data from the International Severe Asthma Registry. Chest. 2020;157(4):790-804. DOI: 10.1016/j.chest.2019.10.053

Torrego A, Sola I, Muñoz AM, Roque IFM, Yepes-Núñez JJ, Alonso-Coello P, et al. Bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev. 2014(3):CD009910. DOI: 10.1002/14651858.CD009910.pub2

Zhou JP, Feng Y, Wang Q, Zhou LN, Wan HY, Li QY. Long-term efficacy and safety of bronchial thermoplasty in patients with moderate-to-severe persistent asthma: a systemic review and meta-analysis. J Asthma. 2016;53(1):94-100. DOI: 10.3109/02770903.2015

Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, Olivenstein R, et al. Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial. BMC Pulm Med. 2011;11:8. DOI: 10.1186/1471-2466-11-8

Álvarez-Gutiérrez F, Blanco-Aparicio M, Plaza V, Cisneros C, García-Rivero J, Padilla A, et al. Consensus document for severe asthma in adults. 2020 update. Open Respir Arch. 2020;2(3):158-174. DOI: 10.1016/j.opresp.2020.03.005

Morales A. Bronchial thermoplasty - A new therapeutic tool for severe asthma. Rev Chil Enferm Respir. 2017;33:113-117. DOI: 10.4067/s0717-73482017000200113

Busse W, Bleecker ER, FitzGerald M, Ferguson GT, Barker P, et al. Three-year safety and efficacy of benralizumab for adolescent patients with severe, uncontrolled asthma: results of the BORA extension study. J Allergy Clin Immunol. 2020;145(Suppl 2):AB174. DOI: 10.1016/j.jaci.2019.12.363

Bonini M, di Paolo M, Bagnasco D, Baiardini I, Braido F, Caminati M, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020;29(156):190137. DOI: 10.1183/16000617.0137-2019

Upham J, Le Lievre C, Jackson D, Masoli M, Wechsler M, Price D, et al. Defining a severe asthma super-responder: findings from a Delphi process [Internet]. Australia: Observational & Pragmatic Research Institute/The University of Queensland; 2020. Disponible en: https://opri.sg/wp-content/uploads/2020/08/Super_responders_poster_ERS.pdf

Erdogan T. Evaluating nonadherence to preventer inhaler therapy in severe asthmatic patients receiving omalizumab. Clin Respir J. 2020;14(12):1153-1158. DOI: 10.1111/crj.13252

Domingo C, Pomares X, Navarro A, Amengual MJ, Monton C, Sogo A, et al. A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients. Br J Clin Pharmacol. 2018;84(2):339-348. DOI: 10.1111/bcp.13453

Nopp A, Johansson SG, Adedoyin J, Ankerst J, Palmqvist M, Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy. 2010;65(1):56-60. DOI: 10.1111/j.1398-9995.2009.02144.x

Vennera MC, Sabadell C, Picado C, Spanish Omalizumab Registry. Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma. Thorax. 2018;73(8):782-784. DOI: 10.1136/thoraxjnl-2017-210017

Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, et al. Incidence of malignancy in patients with moderate to severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560-567. DOI: 10.1016/j.jaci.2014.02.007

Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med. 1995;332(13):868-875. DOI: 10.1056/NEJM199503303321307

Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995;98(2):196-208. DOI: 10.1056/NEJM199503303321307

Kowalski ML, Wojciechowski P, Dziewonska M, Rys P. Adrenal suppression by inhaled corticosteroids in patients with asthma: a systematic review and quantitative analysis. Allergy Asthma Proc. 2016;37(1):9-17. DOI: 10.2500/aap.2016.37.3912

Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs. 1994;47(2):318-331. DOI: 10.2165/00003495-199447020-00007

Weatherall M, James K, Clay J, Perrin K, Masoli M, Wijesinghe M, et al. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy. 2008;38(9):1451-1458. DOI: 10.1111/j.1365-2222.2008.03029.x

Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367(10):904-912. DOI: 10.1056/NEJMoa1203229

Kong-Loke Y, Blanco P, Thavarajah M, Wilson AM. Impact of inhaled corticosteroids on growth in children with asthma: systematic review and meta-analysis. PLoS One. 2015;10(7):e0133428. DOI: 10.1371/journal.pone.0133428

Weatherall M, Clay J, James K, Perrin K, Shirtcliffe P, Beasley R. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology. 2009;14(7):983-990. DOI: 10.1111/j.1440-1843.2009.01589.x

Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217-24. DOI: 10.1183/09031936.02.00269802

Sears MR. Adverse effects of -agonists. J Allergy Clin Immunol. 2002;110(Suppl 6):S322-S328. DOI: 10.1067/mai.2002.129966

Cullinan P, Vandenplas O, Bernstein D. Assessment and management of occupational asthma. J Allergy Clin Immunol Pract. 2020;8(10):3264-3275. DOI: 10.1016/j.jaip.2020.06.031

Baur X, Sigsgaard T, Aasen TB, Burge PS, Heederik D, Henneberger P, et al. Guidelines for the management of work-related asthma. Eur Respir J. 2012;39(3):529-545. DOI: 10.1183/09031936.00096111

Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676-681. DOI: 10.1016/j.jaci.2014.08.020

Mustafa SS, Vadamalai K, Scott B, Ramsey A. Dupilumab as add-on therapy for chronic rhinosinusitis with nasal polyposis in aspirin exacerbated respiratory disease. Am J Rhinol Allergy. 2020:1945892420961969. DOI: 10.1177/1945892420961969

Lailaw T, Mullol J, Canonica G, Bachert C, Han J, Zhang M, et al. Dupilumab improves upper and lower airway outcome measures in patients with CRSwNP with NSAID-ERD: pooled results from the SINUS-24 and SINUS-52 phase 3 trials. W Allergy Organ J. 2020;13(8)100398. DOI: 10.1016/j.waojou.2020.100398

Numata T, Miyagawa H, Nishioka S, Okuda K, Utsumi H, Hashimoto M, et al. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study. BMC Pulm Med. 2020;20(1):207. DOI: 10.1186/s12890-020-01248-x

Caruso C, Colantuono S, Pugliese D, Di Mario C, Tolusso B, Gremese E, et al. Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report. Allergy Asthma Clin Immunol. 2020;16:27. DOI: 10.1186/s13223-020-00423-3

Gibson PG, McDonald VM. Management of severe asthma: targeting the airways, comorbidities and risk factors. Intern Med J. 2017;47(6):623-631. DOI: 10.1111/imj.13441

Shore SA. Obesity and asthma: possible mechanisms. J Allergy Clin Immunol. 2008;121(5):1087-1093; quiz 1094-1095. DOI: 10.1016/j.jaci.2008.03.004

Miethe S, Karsonova A, Karaulov A, Renz H. Obesity and asthma. J Allergy Clin Immunol. 2020;146(4):685-693. DOI: 10.1016/j.jaci.2020.08.011

Maniscalco M, Zedda A, Faraone S, Cerbone MR, Cristiano S, Giardiello C, et al. Weight loss and asthma control in severely obese asthmatic females. Respir Med. 2008;102(1):102-108. DOI: 10.1016/j.rmed.2007.07.029

Kuehn BM. Asthma linked to psychiatric disorders. JAMA. 2008;299(2):158-160. DOI: 10.1001/jama.2007.54-a

Espinosa-Leal FD, Parra-Román M, Méndez NH, Toledo-Nicolás DA, Menez-Díaz D, Sosa-Eroza E, et al. Ansiedad y depresión en asmáticos adultos en comparasión con sujetos sanos. Rev Alerg Mex. 2006;53(6):201-206.

Bedolla-Barajas M, Morales-Romero J, Fonseca-López JC, Pulido-Guillén NA, Larenas-Linnemann D, Hernández-Colín DD. Anxiety and depression in adult patients with asthma: the role of asthma control, obesity and allergic sensitization. J Asthma. 2020;1-9. DOI: 10.1080/02770903.2020.1759087

Oren E, Martínez FD. Stress and asthma: physiological manifestations and clinical implications. Ann Allergy Asthma Immunol. 2020;125(4):372-373.e1. DOI: 10.1016/j.anai.2020.07.022

Heaney LG, Conway E, Kelly C, Gamble J. Prevalence of psychiatric morbidity in a difficult asthma population: relationship to asthma outcome. Respir Med. 2005;99(9):1152-1159. DOI: 10.1016/j.rmed.2005.02.013

Lavoie KL, Bacon SL, Barone S, Cartier A, Ditto B, Labrecque M. What is worse for asthma control and quality of life: depressive disorders, anxiety disorders, or both? Chest. 2006;130(4):1039-1047. DOI: 10.1378/chest.130.4.1039

Sharrad K, Sanwo O, Carson-Chahhoud K, Pike K. Psychological interventions for asthma in children and adolescents. Cochrane Database Syst Rev. 2019;2019(9):CD013420. DOI: 10.1002/14651858.CD013420

Rosati MG, Peters AT. Relationships among allergic rhinitis, asthma, and chronic rhinosinusitis. Am J Rhinol Allergy. 2016;30(1):44-47. DOI: 10.2500/ajra.2016.30.4252

Sedaghat AR, Phipatanakul W, Cunningham MJ. Characterization of aeroallergen sensitivities in children with allergic rhinitis and chronic rhinosinusitis. Allergy Rhinol (Providence). 2014;5(3):143-145. DOI: 10.2500/ar.2014.5.0102

Bousquet J, Schunemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.e3. DOI: 10.1016/j.jaci.2019.06.049

Castro-Rodríguez JA. The Asthma Predictive Index: a very useful tool for predicting asthma in young children. J Allergy Clin Immunol. 2010;126(2):212-216. DOI: 10.1016/j.jaci.2010.06.032

Feng CH, Miller MD, Simon RA. The united allergic airway: connections between allergic rhinitis, asthma, and chronic sinusitis. Am J Rhinol Allergy. 2012;26(3):187-190. DOI: 10.2500/ajra.2012.26.3762

Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J. 2009;33(4):897-906. DOI: 10.1183/09031936.00121308

Dixon AE, Castro M, Gerald LB, Holbrook JT, Henderson RJ, Casale TB, et al. Effect of intranasal corticosteroids on allergic airway disease in asthma. J Allergy Clin Immunol Pract. 2017;5(4):1125-1128.e3. DOI: 10.1016/j.jaip.2017.02.022

Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. N Engl J Med. 2015;372(5):456-463. DOI: 10.1056/NEJMcp1412282

Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sorensen HF, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529-538.e13. DOI: 10.1016/j.jaci.2017.06.014

Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006;61(7):855-859. DOI: 10.1111/j.1398-9995.2006.01068.x

Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943-948. DOI: 10.1111/j.1398-9995.2007.01451.x

Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008;372(9643):1049-1057. DOI: 10.1016/S0140-6736(08)61446-4

Nolte H, Nepper-Christensen S, Backer V. Unawareness and undertreatment of asthma and allergic rhinitis in a general population. Respir Med. 2006;100(2):354-362. DOI: 10.1016/j.rmed.2005.05.012

Lee TJ, Fu CH, Wang CH, Huang CC, Huang CC, Chang PH, et al. Impact of chronic rhinosinusitis on severe asthma patients. PloS One. 2017;12(2):e0171047. DOI: 10.1371/journal.pone.0171047

Canonica GW, Malvezzi L, Blasi F, Paggiaro P, Mantero M, Senna G, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166:105947. DOI: 10.1016/j.rmed.2020.105947

Ceylan E, Gencer M, San I. Nasal polyps and the severity of asthma. Respirology. 2007;12(2):272-276. DOI: 10.1111/j.1440-1843.2006.00964.x

American Lung Association-Asthma Clinical Research Centers’ Writing Committee, Dixon AE, Castro M, Cohen RI, Gerald LB, Holbrook JT, et al. Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma. J Allergy Clin Immunol. 2015;135(3):701-709.e5. DOI: 10.1016/j.jaci.2014.06.038

Patel SS, Casale TB, Cardet JC. Biological therapies for eosinophilic asthma. Expert Opin Biol Ther. 2018;18(7):747-754. DOI: 10.1080/14712598.2018.1492540

Smith KA, Pulsipher A, Gabrielsen DA, Alt JA. Biologics in chronic rhinosinusitis: an update and thoughts for future directions. Am J Rhinol Allergy. 2018;32(5):412-423. DOI: 10.1177/1945892418787132

Liang B, Yi Q, Feng Y. Association of gastroesophageal reflux disease with asthma control. Dis Esophagus. 2013;26(8):794-798. DOI: 10.1111/j.1442-2050.2012.01399.x

Thakkar K, Boatright RO, Gilger MA, El-Serag HB. Gastroesophageal reflux and asthma in children: a systematic review. Pediatrics. 2010;125(4):e925-e930. DOI: 10.1542/peds.2009-2382

Littner MR, Leung FW, Ballard ED, Huang B, Samra NK, Lansoprazole Asthma Study Group. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest. 2005;128(3):1128-1135. DOI: 10.1378/chest.128.3.1128

Lang JE, Holbrook JT, Mougey EB, Wei CY, Wise RA, Teague WG, et al. Lansoprazole is associated with worsening asthma control in children with the CYP2C19 poor metabolizer phenotype. Ann Am Thorac Soc. 2015;12(6):878-885. DOI: 10.1513/AnnalsATS.201408-391OC

Rosen R, Vandenplas Y, Singendonk M, Cabana M, DiLorenzo C, Gottrand F, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66(3):516-554. DOI: 10.1097/MPG.0000000000001889

Bonham CA, Patterson KC, Strek ME. Asthma outcomes and management during pregnancy. Chest. 2018;153(2):515-527. DOI: 10.1016/j.chest.2017.08.029

Cusack RP, Gauvreau GM. Pharmacotherapeutic management of asthma in pregnancy and the effect of sex hormones. Expert Opin Pharmacother. 2021;22:339-349. DOI: 10.1080/14656566.2020

Wang H, Li N, Huang H. Asthma in pregnancy: pathophysiology, diagnosis, whole-course management, and medication safety. Can Respir J. 2020;2020:9046842. DOI: 10.1155/2020/9046842

Meijer WJ, van Noortwijk AG, Bruinse HW, Wensing AM. Influenza virus infection in pregnancy: a review. Acta Obstet Gynecol Scand. 2015;94(8):797-819. DOI: 10.1111/aogs.12680

Siston AM, Rasmussen SA, Honein MA, Fry AM, Seib K, Callaghan WM, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA. 2010;303(15):1517-1525. DOI: 10.1001/jama.2010.479

Takemoto MLS, Menezes MO, Andreucci CB, Knobel R, Sousa LAR, Katz L, et al. Maternal mortality and COVID-19. J Matern Fetal Neonatal Med. 2020;16:1-7. DOI: 10.1080/14767058.2020.1786056

Wang G, Murphy VE, Namazy J, Powell H, Schatz M, Chambers C, et al. The risk of maternal and placental complications in pregnant women with asthma: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2014;27(9):934-942. DOI: 10.3109/14767058.2013.847080

Robijn AL, Murphy VE, Gibson PG. Recent developments in asthma in pregnancy. Curr Opin Pulm Med. 2019;25(1):11-17. DOI: 10.1097/MCP.0000000000000538

Namazy JA, Schatz M. Management of asthma during pregnancy: optimizing outcomes and minimizing risk. Semin Respir Crit Care Med. 2018;39(1):29-35. DOI: 10.1055/s-0037-160621

Nair P, Prabhavalkar KS. Monitoring asthma in pregnancy: diagnosis and treatment. Clin Pulmonary Med. 2020;27(3):67-72. DOI: 10.1097/CPM.0000000000000358

Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337(20):1405-1411. DOI: 10.1056/NEJM199711133372001

Cossette B, Beauchesne MF, Forget A, Lemiere C, Larivee P, et al. Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. Ann Allergy Asthma Immunol. 2014;112(5):459-464. DOI: 10.1016/j.anai.2014.02.010

Namazy J, Cabana MD, Scheuerle AE, Thorp JM, Chen H, Carrigan G, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135(2):407-412. DOI: 10.1016/j.jaci.2014.08.025

Kemp M, Newman J, Challis J, Jobe A, Stock S. The clinical use of corticosteroids in pregnancy. Hum Reprod Update. 2016;22(2):240-259. DOI: 10.1093/humupd/dmv047

Lim A, Stewart K, Konig K, George J. Systematic review of the safety of regular preventive asthma medications during pregnancy. Ann Pharmacother. 2011;45(7-8):931-945. DOI: 10.1345/aph.1P764

Health topics: adolescent health [Internet]. World Health Orgnization; 2010. Disponible en: https://www.who.int/health-topics/adolescent-health/#tab=tab_1

Bitsko MJ, Everhart RS, Rubin BK. The adolescent with asthma. Paediatr Respir Rev. 2014;15(2):146-153. DOI: 10.1016/j.prrv.2013.07.003

De Benedictis D, Bush A. Asthma in adolescence: Is there any news? Pediatric pulmonology. 2017;52(1):129-138. DOI: 10.1002/ppul.23498

Michaud PA, Suris JC, Viner R. The adolescent with a chronic condition. Part II: healthcare provision. Arch Dis Child. 2004;89(10):943-949. DOI: 10.1136/adc.2003.045377

Roberts G, Vázquez-Ortiz M, Knibb R, Khaleva E, Alviani C, Angier E, et al. EAACI guidelines on the effective transition of adolescents and young adults with allergy and asthma. Allergy. 2020;75(11):2734-2752. DOI: 10.1111/all.14459

Hanania NA, King MJ, Braman SS, Saltoun C, Wise RA, Enright P, et al. Asthma in the elderly: Current understanding and future research needs-a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol. 2011;128(Suppl 3):S4-S24. DOI: 10.1016/j.jaci.2011.06.048

González-Díaz SN, Villarreal-González RV, de Lira-Quezada CE, Guzmán-Avilan RI. Outcome measures to be considered on asthma in elderly. Curr Opin Allergy Clin Immunol. 2019;19(3):209-215. DOI: 10.1097/ACI.0000000000000525

Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-118. DOI: 10.1016/j.jaci.2020.04.006

Choi YJ, Park JY, Lee HS, Suh J, Song JY, Byun MK, et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19. Eur Respir J. 2021;57(3):2002226. DOI: 10.1183/13993003.02226-2020

Lee SC, Son KJ, Han CH, Jung JY, Park SC. Impact of comorbid asthma on severity of coronavirus disease (COVID-19). Sci Rep. 2020;10(1):21805. DOI: 10.1038/s41598-020-77791-8

Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020;8(11):1106-1120. DOI: 10.1016/S2213-2600(20)30415-X

Izquierdo JL, Almonacid C, González Y, Del Río-Bermúdez C, Ancochea J, Cárdenas R, et al. The impact of COVID-19 on patients with asthma. Eur Respir J. 2021;57(3);2003142. DOI: 10.1183/13993003.03142-2020

Peters MC, Sajuthi S, Deford P, Christenson S, Ríos CL, Montgomery MT, et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020;202(1):83-90. DOI: 10.1164/rccm.202003-0821OC

Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58(3):155-168. DOI: 10.1016/j.resinv.2019.12.005

Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146(1):203-206.e3. DOI: 10.1016/j.jaci.2020.04.009

Domingo C, Pomares X, Amengual M, Oller M. Successful withdrawal of omalizumab in a patient with severe asthma: free IgE as a possible biomonitor. Eur J Inf Syst. 2014;12(2):389-393. DOI: 10.1177/1721727X1401200217

Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742-1751 e7. DOI: 10.1016/j.jaci.2018.09.033

Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46-59. DOI: 10.1016/S2213-2600(18)30406-5

Publicado

2021-07-26